Skip to Content

Zykadia Approval History

FDA Approved: Yes (First approved April 29, 2014)
Brand name: Zykadia
Generic name: ceritinib
Dosage form: Capsules
Company: Novartis Pharmaceuticals Corporation
Treatment for: Non-Small Cell Lung Cancer

Zykadia (ceritinib) is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.

Development History and FDA Approval Process for Zykadia

DateArticle
May 26, 2017Approval Novartis Receives FDA Approval for Expanded Use of Zykadia in First-Line ALK-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)
Apr 29, 2014Approval FDA Approves Zykadia (ceritinib) for Metastatic Non-Small Cell Lung Cancer

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide